Search Results for:
-
Astrazeneca Investing in New R&D Center in Cambridge, UK
That is the vision Menelas Pangalos, executive vice president of innovative medicines at Astrazeneca plc, outlined as he discussed the announcement that the company's new £330 million (US$514 million) global R&D center and corporate headquarters is to be built on the Cambridge Biomedical CampusBy Nuala Moran | BioWorld Today | Wednesday, June 19, 2013 -
Astrazeneca Investing in New R&D Center in Cambridge, UK
That is the vision Menelas Pangalos, executive vice president of innovative medicines at Astrazeneca plc, outlined as he discussed the announcement that the company's new £330 million (US$514 million) global R&D center and corporate headquarters is to be built on the Cambridge Biomedical CampusBy Nuala Moran | BioWorld International | Wednesday, June 19, 2013 -
Conatus Pharma Seeks $69M for Liver Drug Emricasan
A third Conatus co-founder, Charles Cashion, senior vice president of finance, chief financial officer and secretary, also held similar roles at Idun...Meanwhile, Gary Burgess, senior vice president of clinical research and chief medical officer, joined Conatus in 2011 from Pfizer, where he oversaw the assimilation of Idun, including data integration, clinical oversight of ongoing Phase II studies, development of clinical plans and registration strategies for emricasanBy Marie Powers | BioWorld Today | Monday, June 17, 2013 -
Earnouts and Back-Ended Deals Expected to Continue
We don't spend time arguing about forecasts," said Michael D. Step, senior vice president of corporate development at Santarus Inc., of San Diego...We wanted them to compete on the back end of the deal to prove their interest," McDavid Stilwell, Orexigen's vice president of corporate communications and business development, told the audienceBy Brian Orelli | BioWorld Today | Friday, June 14, 2013 -
'Tea'-ing Off in China? Celgene Shares Lessons from Hot Market
Called "Demystifying Product Development in China," the hour-long panel sought to make clearer the regulatory landscape there, and along with Zeldis, speakers included RuiPing Dong, head of emerging markets for Merck Research Laboratories, and Kent Thoelke, vice president of scientific and medical affairs for the contract research organization PRA InternationalBy Randy Osborne | BioWorld Today | Friday, June 14, 2013 -
$0.00Audio Conferences | Wednesday, June 12, 2013
-
Appointments and Advancements
Curis Inc., of Lexington, Mass., named Mani Mohindru vice president of corporate strategy and investor relations...Mirna Therapeutics Inc., of Austin, Texas, appointed Sinil Kim vice president of oncology and chief medical officerBioWorld Today | Wednesday, June 12, 2013 -
Astrazeneca Shells Out $560M for Pearl's Phase III COPD Bid
The intention is to move forward and get that triple combination into development quickly," said Lyn Baranowski, Pearl's vice president of business developmentBy Randy Osborne | BioWorld Today | Tuesday, June 11, 2013 -
$0.00Audio Conferences | Thursday, June 6, 2013
-
China Biologics Executives See a Better Way Forward
Hans-Peter Grau, vice president for business development and key account management for Asia, contract manufacturing biopharmaceuticals at Boehringer Ingelheim Biopharmaceuticals GmbH, reminded the audience of the rapid transformation the agency has been facingBy Larry Schuster | BioWorld Today | Wednesday, June 5, 2013 -
T-VEC Not Top Banana, but Still in the Pudding
The proof of the pudding will come with mature OS data, which are not likely to report until the end of the year, according to David Chang, Amgen's vice president of global developmentBy Marie Powers | BioWorld Today | Tuesday, June 4, 2013 -
Adaptive Trial Designs Could Save Companies Millions
Why adapt the sample size, for instance, when it "isn't recognized as an explanation as to why we're failing in Phase III studies," Vladimir Dragalin, senior vice president of software development & consulting at Aptiv Solutions, a CRO specializing in adaptive designs, told BioWorld InsightBy Brian Orelli | BioWorld Insight | Monday, June 3, 2013 -
Appointments and Advancements
Achillion Pharmaceuticals Inc., of New Haven, Conn., appointed David Apelian executive vice president and chief medical officerBioWorld Today | Monday, June 3, 2013 -
Taking a Hollywood Cue, Will Congress Remake a Classic?
Negotiating Medicare drug prices could save the federal government $230 billion to $541 billion by 2022, according to a Center for Economic and Policy Research report released earlier this year. (See BioWorld Today, Feb. 19, 2013.) Negotiations are already part of the script, testified Richard Smith, executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMABio Perspectives | Wednesday, May 29, 2013 -
Taking a Hollywood Cue, Will Congress Remake a Classic?
Negotiating Medicare drug prices could save the federal government $230 billion to $541 billion by 2022, according to a Center for Economic and Policy Research report released earlier this year. (See BioWorld Today, Feb. 19, 2013.) Negotiations are already part of the script, testified Richard Smith, executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMABy Mari Serebrov | BioWorld Today | Wednesday, May 29, 2013 -
Oral Exam: Takeda's MM Bid Enters Phase III Combo Trial
The study includes a planned follow-up of up to five years," Dixie Esseltine, vice president of global clinical development for Takeda, told BioWorld Today, adding that MLN9708 is differentiated from competitors in three waysBy Randy Osborne | BioWorld Today | Friday, May 24, 2013 -
Jennerex Plucks $21.6M Private Placement; Is IPO Up Next?
Chris Peetz, vice president of corporate development at privately held Jennerex, said the financing will extend the company's runway into the first half of 2014, following the release of Phase IIb data at the end of this yearBy Marie Powers | BioWorld Today | Friday, May 24, 2013 -
Salix's Topical Budesonide a Hit in Phase III Studies in UC
We believe this combination of using a high potency topical steroid with a delivery formulation that covers both UP and UPS would be a valuable addition to the available therapies for these patients," said Bill Forbes, executive vice president of medical, research and development and chief development officerBy Jennifer Boggs | BioWorld Today | Thursday, May 23, 2013 -
Found in Translation: Series A Brings in $45M for Effector
Siegfried Reich, senior vice president of drug discovery...Kevin Eastwood, senior vice president of business developmentBy Jennifer Boggs | BioWorld Today | Tuesday, May 21, 2013 -
Oncos Targets Solid Tumors With Oncolytic Virus Approach
Co-founders included inventor Akseli Hemminki, a professor and founder of the Cancer Gene Therapy Group at the University of Helsinki, Antti Vuolanto, now vice president of manufacturing, and founding CEO Pekka Simula, who now serves as the company's chief operating officerBy Marie Powers | BioWorld Today | Monday, May 20, 2013
Category
Current Filters
- xvice president
Related Keywords
Categories
- x BioWorld Today (6866)
- x BioWorld International (590)
- x BioWorld Insight (297)
- x BioWorld Genomics Review (218)
- x Bio Perspectives (156)
- x Executive Compensation Report (47)
- x State of the Industry Report (21)
- x Top 25 Drug Report (9)
- x Biotech Innovations (8)
- x Recorded (4)
- x Upcoming (2)
- x RNAi Report (2)
- x Market-Leading Biotech Drugs (2)
- x BioWorld Executive Compensation Report 2013 (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.
